Background. Burkholderia pseudomallei, the causative agent of the high-mortality disease melioidosis, is a gram-negative bacterium that is naturally resistant to many antibiotics. There is no vaccine for melioidosis, and effective eradication is reliant on biphasic and prolonged antibiotic administration. The carbapenem drug meropenem is the current gold standard option for treating severe melioidosis. Intrinsic B. pseudomallei resistance toward meropenem has not yet been documented; however, resistance could conceivably develop over the course of infection, leading to prolonged sepsis and treatment failure.
Burkholderia pseudomallei is the causative agent of melioidosis, and one of the most intrinsically drug-resistant bacterial pathogens [1] . Eradication relies on a lengthy antibiotic regimen, as no vaccine is available [2, 3] . Even with antibiotic treatment, rapid diagnosis, and high healthcare standards, case fatality rates are 10% in Northern Australia and 40% in Southeast Asia [4, 5] , the 2 regions with the highest reported melioidosis rates [6, 7] . Burkholderia pseudomallei is a significant yet underreported cause of morbidity and mortality in tropical and subtropical regions, with recent modeling suggesting mortality rates on par with measles (~89 000 deaths/year) and substantially higher than dengue [7] .
Treatment is biphasic, comprising an initial intensive intravenous (IV) phase of a minimum of 10-14 days, then a prolonged oral eradication phase lasting up to 6 months. The carbapenems imipenem and meropenem have the lowest minimum inhibitory concentrations (MICs) against B. pseudomallei, with in vitro time-kill studies showing that carbapenems perform better than ceftazidime [8] . Meropenem is recommended for life-threatening sepsis cases requiring intensive care therapy, although there is no clinical evidence that ceftazidime is inferior to meropenem for patients with melioidosis who are not critically ill, and ceftazidime remains the drug of choice for initial IV therapy [2, 3] . During the eradication phase, the preferred treatment is trimethoprim-sulfamethoxazole (TMP-SMX), with amoxicillin-clavulanate or doxycycline used as alternatives when required.
Due to limited treatment options, the development of antibiotic resistance during infection is a significant event that can lead to treatment failure. Unlike many other infectious diseases, melioidosis is largely noncommunicable, with infections typically acquired following contact with contaminated soil or water [1] . As such, resistance only emerges during treatment rather than by transmission from another individual or animal [9] . To date, all B. pseudomallei antibiotic resistance mechanisms are conferred by chromosomal alterations. Ceftazidime resistance occurs by upregulation or alteration of the β-lactamase PenA [10] [11] [12] [13] [14] or the loss of penicillin-binding protein 3 (PBP3) (BPSS1219) [15] . Certain penA point mutations cause imipenem resistance [16] , and missense and promoter mutations affecting penA confer amoxicillin-clavulanate resistance [11, 13] . Upregulation of the AmrAB-OprA, BpeEF-OprC, or BpeAB-OprB multidrug efflux pumps also contributes to antibiotic resistance in B. pseudomallei and, in combination with mutations in methylation or metabolism pathways, lead to doxycycline or TMP-SMX resistance, respectively [12, 17] .
We recently sequenced isogenic B. pseudomallei strain pairs with decreased susceptibility toward meropenem from 3 cases [18] . Here, we identified the mutations leading to this decreased meropenem susceptibility, and functionally characterized the mechanisms. We then reviewed approximately 1000 melioidosis cases enrolled in the Darwin Prospective Melioidosis Study (DPMS), a 30-year ongoing study of melioidosis cases in the endemic "Top End" region of Australia [5] . The intent was to identify additional DPMS patients with infections exhibiting decreased meropenem susceptibility. A focus was placed on patients with persistent culture positivity or recrudescent or relapsing infections, irrespective of meropenem treatment history. Where available, longitudinal isolates were examined to identify temporal emergence of decreased susceptibility. Comparative genomics was used to identify the mechanisms underpinning this altered phenotype.
METHODS

Clinical Histories and Isolates
Patient histories are detailed in Supplementary Text 1. Unless otherwise stated, patients were enrolled in the DPMS. All underwent prolonged antibiotic treatment, often with multiple, repeated courses of antibiotics. Some patients took leave from hospital during treatment, several on >1 occasion. Ethics approvals are described elsewhere [5, 19] .
Culture Conditions, DNA Isolation, and Whole-Genome Sequencing Unless stated otherwise, culture conditions, DNA extraction, and whole-genome sequencing (WGS) were performed as outlined previously [20] .
Meropenem MIC Determination
Meropenem MICs were determined using Etest (bioMérieux). Clinical and Laboratory Standards Institute guidelines do not list meropenem MIC values for B. pseudomallei. Based on previous testing of 234 primary [21] B. pseudomallei isolates, and establishment of an epidemiological cutoff value [22] , we categorized decreased meropenem susceptibility as MIC ≥3 µg/mL.
Reference Genome Assembly
High-quality genomes for patients (P) P608, P726, and P797 [18] were used to identify the molecular basis of decreased meropenem susceptibility in these cases. For other patients, reference genomes were assembled to improved draft quality using MGAP version 1.0 software (https://github.com/dsarov/ MGAP---microbial-genome-assembler-pipeline).
Identification of Molecular Targets Conferring Decreased Meropenem Susceptibility
Comparative genomics was performed using SPANDx version 3.1.2 software [23] to identify single-nucleotide polymorphisms (SNPs), insertions/deletions (indels), large deletions, and gene duplications between sensitive and decreased susceptibility isolates. Where available, the initial isolate from each patient was used as the reference; otherwise B. pseudomallei K96243 [24] was used for read mapping and variant annotation. Rearrangements were assessed using Mauve version 2.4.0 software [25] .
Knockouts and Reverse-Transcription Quantitative Polymerase Chain Reaction
Scarless gene knockouts were created as detailed previously [26] using primers described elsewhere [27] . Reverse-transcription quantitative polymerase chain reaction (RT-qPCR) of amrB expression was performed as previously detailed [27] , using redesigned primers amrB_forward 5ʹ-TGTTCGCATGGGTGA TCTCC-3ʹ, a mrB_reverse 5ʹ-GACCGATTCCTCGACGA CCT-3ʹ, and amrB_probe 5ʹFAM-TGTTCATCATGCTGGG CGGCATC-3ʹ BHQ-1. No preamplification of nucleic acid was required for detection and quantification. To measure the role of induction on amrAB-oprA expression, meropenem was included at the subinhibitory concentration of 0.25 µg/mL.
Data Access
All WGS data are available under BioProject accession numbers PRJNA272882, PRJNA300580, PRJNA393909, PRNJA397943, and PRJNA412120.
RESULTS
Decreased Meropenem-Susceptible Isolates Have an Altered AmrR Efflux Pump Regulator
We have recently identified 3 DPMS patients (P608, P726, and P797) with severe melioidosis and prolonged blood culture positivity who harbored B. pseudomallei strains exhibiting decreased meropenem susceptibility following meropenem treatment [18] . These patients were repeatedly, but not continuously, blood culture positive for 64, 89, and 454 days, respectively (Supplementary Figure 1) . P726 and P797 ultimately died, whereas P608 eventually cleared their infection. The difficulty in eradicating these infections despite prolonged, aggressive antibiotic therapy prompted us to investigate MICs toward clinically relevant antibiotics. All initial isolates were sensitive to meropenem (MIC = 0.5-0.75 µg/mL), whereas the latter isolates had increased MICs (3-8 µg/mL; Figure 1 ; Table 1 ). P608 and P797 isolates also developed resistance toward TMP-SMX at 24/456 µg/mL and 4/76 µg/mL, respectively.
For all 3 cases, high-quality closed or close-to-closed assemblies [18] enabled comprehensive identification of all genetic variants between pairs (Supplementary Table 1) . A single gene, amrR, was mutated in all latter but not initial isolates ( Figure 2 ; Table 2; Supplementary Table 1) . AmrR is the local TetRtype regulator of the resistance-nodulation-division (RND) efflux pump AmrAB-OprA, which confers intrinsic aminoglycoside and macrolide resistance in B. pseudomallei [28] . The latter P608 isolate encodes a 4-residue in-frame deletion (Ala153_Asp156del), the latter P726 isolate possesses a 4-residue in-frame deletion (Val60_Cys63del), and 2 latter isolates from P797 encode a Gly30Asp missense mutation. No structural alterations, large deletions, or duplications were observed.
Functional Characterization Confirms amrAB-oprA Upregulation in AmrR Mutants
Scar-less amrR gene knockouts were created from 2 mutant isolates (MSHR4083 [P608] and MSHR6755 [P726]) and 1 wild-type control (MSHR5864 [P726]). The amrR removal from these strains led to an MIC value of 3 µg/mL, regardless of parental strain MIC.
Next, strains MSHR4083, MSHR3763, MSHR5864, MSHR6755, and their corresponding amrR knockouts (where available) were tested for increased amrB expression both with and without the presence of meropenem using RT-qPCR. For wild-type strains, amrB expression was barely detectable regardless of meropenem presence or absence. All other strains with amrR mutations or deletions showed significant amrB upregulation (range, 10-to 30-fold) in the presence of subinhibitory (0.25 µg/mL) meropenem concentrations, but no significantly increased expression in the absence of meropenem.
Additional Strains With Increased Meropenem MICs Also Encode amrR Mutations
Almost all primary isolates retrieved from the DPMS cohort have previously been screened for antibiotic resistance toward the clinically relevant drugs used in treatment [21] . Testing of latter strains from cases with slow clinical response or cultureconfirmed recrudescent infection identified a further 4 DPMS patients (P179, P215, P337, P989) with elevated meropenem MICs. We also examined B. pseudomallei isolates from 4 non-DPMS cases: 2 cystic fibrosis (CF) patients with previously documented elevated meropenem MICs [12] , 1 case (pre-DPMS 89) infected prior to DPMS commencement, and a fourth (QP09) from a different study site.
In all but 2 cases, isolates with decreased meropenem susceptibility encoded missense, frameshift, or nonsense mutations in amrR ( Figure 2 ; Table 2 ; Supplementary Text 1; Supplementary Table 1) . Curiously, 2 strains with decreased meropenem susceptibility were retrieved from P179, yet only 1 (MSHR0678) possessed an amrR mutation. The other strain, MSHR0800, instead encoded a frameshift mutation in the LysR-type regulator bpeR (BPSL0812; L85fs), the local transcriptional regulator of the BpeAB-OprB RND efflux pump (Table 2) . A whole-genome SNP and indel phylogeny of 6 isolates from P179 showed that these strains developed decreased meropenem susceptibility independently (Supplementary Figure 2) . A mutant bpeR was also observed in MSHR0937 from P215 (D176A), which otherwise did not encode any mutations linked to decreased meropenem susceptibility (Table 2; Supplementary Table 1;  Supplementary Text 1) . In addition to a truncated amrR (K13fs), MSHR1300 (P337) encoded a missense mutation in bpeT (BPSS0290; S311R), the local LysR-type regulator of the BpeEF-OprC RND efflux pump. Interestingly, the latter isolate from P989 was a 2:1 mixture of 2 strains containing either a S166P substitution or an A145 frameshift in AmrR (Table 2 
Resistance Toward Other Antibiotics
MIC determination identified multidrug resistance development in 8 cases, with acquired resistance or decreased susceptibility toward ceftazidime, TMP-SMX, amoxicillin-clavulanate, or doxycycline emerging in latter strains ( Table 1 ). The most common was TMP-SMX (n = 4), and MICs ranged from 4 µg/mL to ≥32 µg/mL. In the P608 mutant, a missense SNP affected dut (BPSL0903; dnaS), which encodes for deoxyuridine 5ʹ-triphosphate nucleotidohydrolase, an enzyme involved in pyrimidine metabolism. Although not functionally characterized in this study, the G91A substitution likely contributes to high-level TMP-SMX resistance in this isolate as no other mutations separated this pair. The P797 mutant encoded an in-frame deletion (D110_G116del) in a putative phosphoesterase (BPSL2263); b From Sarovich et al [11] .
c Antibiotic sensitivity testing (excluding MP) for this patient was performed using the Vitek 2 system.
d From Viberg et al [12] .
this mutation was not present in the TMP-SMX-sensitive initial and midpoint isolates and was the only coding mutation separating latter and midpoint strains (Supplementary Table 1 ). TMP-SMX resistance was also observed in both CF cases [12, 17] . In CF11 (≥32 µg/mL), TMP-SMX resistance is most likely conferred by mutations affecting Ptr1 (R20-A22 insertion) and BpeS (co-regulator of BpeEF-OprC; V40I and R247L). The mechanism of TMP-SMX resistance in CF9 is not yet known, but may be attributed to missense SNPs in dut (N99S) or metF (N162P; Supplementary Text 1) [12] . Doxycycline resistance was observed in amrR mutants from pre-DPMS 89 and CF9 (48 µg/mL). Consistent with earlier work [27] , the amrR-mutated strain from CF9 encodes a frameshift in BPSL3085, and in pre-DPMS 89, 2 missense mutations affect this gene (Supplementary Text 1) . Pre-DPMS 89 and P215 strains also encode PenA T147A, previously associated with high-level imipenem (32 µg/mL) and amoxicillin-clavulanate (32 µg/mL) resistance in B. pseudomallei Bp1651 [16] ; however, all 3 strains in our study (MSHR0052, MSHR0664, and MSHR0937) remained sensitive to imipenem (MIC = 0.5 µg/mL), indicating that this mutation by itself does not confer imipenem resistance. Interestingly, meropenem MICs showed no correlation with imipenem MICs, suggesting different pharmacodynamics of these 2 carbapenems in B. pseudomallei.
Decreased ceftazidime susceptibility was seen in P215 and CF11 (8-12 µg/mL), and high-level resistance (≥256 µg/mL) has previously been described in P337. A 10× duplication of penA [12] , and a PenA C69Y mutant [11] , are responsible for the elevated ceftazidime MICs in CF11 and P337, respectively. The molecular basis for decreased ceftazidime susceptibility in P215
is not yet known, although altered penA copy number and missense or promoter mutations can be ruled out, as can mutations in PBP3. Based on genome comparison of the isogenic P215 pair, we propose that a deleterious frameshift mutation in spoT, the enzyme responsible for ppGpp metabolism, may cause ceftazidime resistance by altering growth kinetics (Supplementary Table 1 ).
DISCUSSION
Meropenem is an invaluable antibiotic, particularly for critically ill melioidosis patients requiring intensive care [29] . Primary resistance toward this antibiotic fortunately remains to be identified in B. pseudomallei [21] . We recently documented 3 cases whereby patients had extended and repeated episodes of blood culture positivity despite aggressive antibiotic treatment. Alarmingly, all were infected with B. pseudomallei strains that had developed reduced sensitivity toward meropenem during treatment (MIC = 3-8 µg/mL vs 0.5-0.75 µg/mL) [18] . A complicating feature was patient self-discharge from the hospital on multiple occasions, which greatly shortened intended initial IV antibiotic regimens based on Royal Darwin Hospital melioidosis treatment guidelines [30] . All had difficulty clearing their B. pseudomallei infections, and 2 ultimately died.
Here, we expand upon our earlier work by identifying and functionally characterizing the molecular basis for decreased meropenem susceptibility in B. pseudomallei isolates retrieved c In-frame indel shortens protein length from 223 to 219 residues.
d Isolates from this patient were intentionally sequenced from a potentially mixed population to capture population diversity. For MSHR9021, 2 AmrR mutants, S166P and A145fs, were present at ratios of approximately 66% and 33%, respectively (Supplementary Figure 3) . No AmrR mutants or mixtures were observed in the initial strain from this patient. e Frameshift indel shortens protein length from 223 to 183 residues.
f Frameshift indel shortens protein length from 223 to 117 residues.
g Frameshift indel increases protein length from 223 to 285 residues.
from 11 melioidosis cases. Five cases refractory to treatment were identified following a comprehensive review of approximately 1000 patients enrolled in the DPMS, an ongoing study of melioidosis cases in the Northern Territory [5] . Three additional cases not enrolled in the DPMS were also included. A focus was placed on those patients with persistent culture positivity, or recrudescent or relapsing infections. These cases span 26 years and represent melioidosis patients living in 2 Australian states. The mutated strains were unrelated according to phylogenomic analysis, demonstrating that decreased meropenem susceptibility can potentially arise in any B. pseudomallei isolate given the right selective pressures. We catalogued all genome-wide alterations separating the initial susceptible isolates from their mutated counterparts. Remarkably, isolates with decreased meropenem susceptibility from 10 cases had accrued nonsynonymous mutations within a single gene, amrR, which encodes the TetR-type regulator of RND efflux pump AmrAB-OprA. In the remaining case, we observed an alteration in bpeR, the LysR-type regulator of the RND efflux pump BpeAB-OprB; this mutation was also observed in 1 of 2 isolates retrieved from P179 that encoded no mutations in amrR yet exhibited decreased meropenem susceptibility. One other patient, P337, harbored an amrRmutated isolate (MSHR1300) that also encoded an altered bpeT, the LysR-type regulator of the RND efflux pump BpeEF-OprC. These results show that mutations affecting RND efflux pump regulation, particularly AmrAB-OprA, cause increased MICs toward meropenem. Our findings provide a striking example of convergent evolution conferring a given antibiotic resistance phenotype.
To understand the link between RND efflux pump dysregulation and decreased meropenem susceptibility, we compared amrB expression levels in mutated and wild-type strains. The dramatic upregulation of amrB in the absence of a functional amrR (approximate 10-to 30-fold increase) during meropenem induction is consistent with the regulatory role of AmrR on AmrAB-OprA, and shows that meropenem acts as a substrate for this efflux pump. A similar phenomenon has been documented in Pseudomonas aeruginosa [31, 32] and Acinetobacter baumannii [33] , where overexpression of the MexAB-OprM and AdeABC efflux pumps, respectively, led to decreased meropenem susceptibility. These studies also found that dysregulation of other efflux pump regulators contributed to this phenotype by increasing expression of other RND efflux pumps. We observed 3 isolates with mutations in other efflux pump regulators (bpeT in MSHR1300 and bpeR in MSHR0800 and MSHR0937). Hayden et al also identified an 800-kb inversion affecting bpeT in B. pseudomallei 354e, which increased its meropenem MIC to 6 μg/mL [34] . Taken together, these findings suggest that all 3 RND efflux pumps in B. pseudomallei can potentially efflux meropenem, although to what extent is not yet known. The complex regulatory network controlling expression of these pumps is not well understood [17] , and further work is needed to determine the precise roles of AmrR, BpeR, and BpeT in regulating efflux pump expression in B. pseudomallei, including unraveling the mechanism underpinning the induction of AmrAB-OprA expression in the presence of meropenem.
Cross-resistance has been described in many pathogenic bacterial species. For example, the first-documented methicillin-resistant Staphylococcus aureus clones are thought to have become methicillin-resistant approximately 14 years before the use of this antibiotic in clinical practice, with resistance driven by first-generation β-lactam rather than methicillin use [35] . In this vein, it is noteworthy that pre-DPMS 89 and P337 harbored strains with reduced meropenem sensitivity yet were never treated with this drug, although they were both given doxycycline and P337 was also administered TMP-SMX. These antibiotics are known substrates for at least 1 of the B. pseudomallei RND efflux pumps [17, 27] . In pre-DPMS 89, the latter strain was doxycycline resistant (MIC = 48 µg/mL) and, in P337, decreased TMP-SMX susceptibility (3 µg/mL) was seen (Table 1) . Thus, we postulate that the increased MICs toward doxycycline or TMP-SMX led to meropenem cross-resistance in these cases. Interestingly, cross-resistance was not observed with imipenem, indicating that these 2 carbapenems should be treated as separate drugs for the purposes of melioidosis treatment and isolate MIC testing, a substantial shift in current treatment dogma. The complex interplay of antibiotics and their cellular targets highlights the enigmatic role that multidrug efflux systems can play in the development of antibiotic resistance in many bacterial pathogens, including B. pseudomallei. Furthermore, our results show that resistance toward clinically relevant antibiotics can emerge during melioidosis treatment even when those antibiotics are not administered to the patient. A more intimate understanding of the mechanisms of crossresistance in B. pseudomallei is needed to better identify and treat such mutants as they emerge under selection.
Current culture-based methodologies take 24-72 hours for resistance determination, significantly delaying effective treatment administration [36] . Predicting resistance using nucleic acid-based approaches allows culture-independent, and thus more rapid, antibiotic resistance detection [37] . Due to the large number of mutations associated with decreased meropenem susceptibility, and the strong likelihood of additional novel mutations underpinning this phenotype, methods that identify multiple mutations simultaneously will have the most value in the clinical setting. Portable, close-to-real-time next-generation sequencing of amplicons or bacterial genomes (eg, Oxford Nanopore sequencing [38] ), or RT-qPCR assays that detect RND efflux pump upregulation, have the advantages of rapid turnaround time, low per-sample cost, and broad target detection. We have preliminarily shown that amrB is dramatically upregulated (10-to 30-fold) in amrR-mutated B. pseudomallei strains exhibiting decreased meropenem susceptibility.
Additional PCR assays targeting the BpeAB-OprB and BpeEFOprC RND efflux pumps in B. pseudomallei may be useful in rapidly identifying bpeR and bpeT mutants, and we are currently evaluating a novel triplex RT-qPCR assay for this purpose (Webb et al, manuscript in preparation).
Our study raises several unanswered questions. First, the precise clinical consequence of decreased meropenem susceptibility in B. pseudomallei is not yet clear. Our study focused on persistently blood culture-positive cases, or those that had recrudesced or relapsed, and excluded acute, fatal infections or cases where eradication was achieved within the expected timeframe. It is possible that decreased meropenem susceptibility also occurs in these cases but remains undiagnosed. However, we deem this unlikely given that this phenotype is rarely identified despite extensive testing. Second, it is unclear whether an increased meropenem MIC precludes using this antibiotic in these cases, or what alternative regimens may be more effective. We showed that decreased susceptibility toward meropenem poses a greater risk for developing multidrug resistance due to cross-resistance toward other antibiotics. It is noteworthy that all strains with decreased meropenem susceptibility remained sensitive to imipenem, suggesting that cross-resistance between these carbapenems does not occur.
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